Advertisement

Related Videos

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Advertisement

Advertisement




Oct
01
Today In Oncology
Cleveland Clinic London Appoints Oncology Vice Chief
NCCN Models How to Tailor Cancer Care for Different Regions During 2026 World Cancer Congress
IARC Panel Provides International Determination on Lung Cancer Screening Benefits and Harms
Multicancer Early Detection Screening Does Not Reduce Overall Late-Stage Cancer Diagnosis
Can Long Distance Running Be a Risk Factor for Early-Onset Colorectal Cancer?
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo